Drug Profile
Research programme: prostate cancer therapy - Eli Lilly and Company/Millennium Pharmaceuticals
Alternative Names: Prostate cancer therapy research programme - Eli Lilly and Company/Millennium PharmaceuticalsLatest Information Update: 07 Apr 2003
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Millennium Pharmaceuticals
- Developer Eli Lilly and Company; Takeda Oncology
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 07 Apr 2003 No development reported - Preclinical for Prostate cancer in USA (unspecified route)
- 05 Jan 2000 Millennium Pharmaceuticals has delivered a validated drug screening target to Lilly
- 20 Aug 1999 New profile